Cytomation Presents at European Drug Discovery Technology Congress

Apr 23, 2001, 01:00 ET from Cytomation Inc.

    STUTTGART, Germany, April 23 /PRNewswire Interactive News Release/ --
 Global bioinstrumentation and software leader Cytomation Inc. will showcase
 the latest in drug discovery technology this week at a scientific congress
 drawing industry leaders from the world's top 20 pharmaceutical companies.
     Cytomation will join more than 55 top-level speakers, 80 exhibitors and
 850 participants at Drug Discovery Technology Europe 2001 to discuss the major
 strategic, technology and partnering challenges that face the
 biopharmaceutical industry over the next decade.  Much of the congress, which
 runs 23-26 April, will focus on the next phase of the genomics revolution,
 highlighting new technologies and their impact on target selection, lead
 identification and candidate survival.
     With offices in the United States, Germany and Australia, Cytomation
 designs and manufactures high performance MoFlo(R) Cytometers and Ultra-High-
 Speed Cell Sorters, which use state-of-the-art laser optics, fluidics,
 electronics and robotics to analyze, separate and collect tens of thousands of
 cells per second. Developed to sort chromosomes for the Human Genome Project,
 Cytomation's instruments are in use at nearly 200 sites in the United States,
 Canada, Europe, Japan, Australia and Argentina for applications such as HIV
 and cancer research, stem cell analysis, livestock sex selection, crop
 improvement and drug discovery.
     Drug discovery is a rapidly growing market for Cytomation, which offers a
 modular, custom configured platform, known as MoFlo(R)HTS.  Capable of
 analyzing more than 100,000 single live cells or beads per second, MoFlo(R)HTS
 features MoSkeeto(TM) automated multi-well sample delivery, CyCLONE(R) single-
 cell deposition, CytoBorg(TM) input/output plate movement, SortMaster(TM)
 controls for walk-away sorting, and CytoShield(TM) biohazard containment for
 operator safety and sample integrity. With bioinformatics-enabled Summit(TM)
 Software, the platform offers hit detection based on up to 32 parameters per
 cell or bead, data mining, open architecture for data management and exchange,
 and control-setting capture for data validation.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X15688188
 
 

SOURCE Cytomation Inc.
    STUTTGART, Germany, April 23 /PRNewswire Interactive News Release/ --
 Global bioinstrumentation and software leader Cytomation Inc. will showcase
 the latest in drug discovery technology this week at a scientific congress
 drawing industry leaders from the world's top 20 pharmaceutical companies.
     Cytomation will join more than 55 top-level speakers, 80 exhibitors and
 850 participants at Drug Discovery Technology Europe 2001 to discuss the major
 strategic, technology and partnering challenges that face the
 biopharmaceutical industry over the next decade.  Much of the congress, which
 runs 23-26 April, will focus on the next phase of the genomics revolution,
 highlighting new technologies and their impact on target selection, lead
 identification and candidate survival.
     With offices in the United States, Germany and Australia, Cytomation
 designs and manufactures high performance MoFlo(R) Cytometers and Ultra-High-
 Speed Cell Sorters, which use state-of-the-art laser optics, fluidics,
 electronics and robotics to analyze, separate and collect tens of thousands of
 cells per second. Developed to sort chromosomes for the Human Genome Project,
 Cytomation's instruments are in use at nearly 200 sites in the United States,
 Canada, Europe, Japan, Australia and Argentina for applications such as HIV
 and cancer research, stem cell analysis, livestock sex selection, crop
 improvement and drug discovery.
     Drug discovery is a rapidly growing market for Cytomation, which offers a
 modular, custom configured platform, known as MoFlo(R)HTS.  Capable of
 analyzing more than 100,000 single live cells or beads per second, MoFlo(R)HTS
 features MoSkeeto(TM) automated multi-well sample delivery, CyCLONE(R) single-
 cell deposition, CytoBorg(TM) input/output plate movement, SortMaster(TM)
 controls for walk-away sorting, and CytoShield(TM) biohazard containment for
 operator safety and sample integrity. With bioinformatics-enabled Summit(TM)
 Software, the platform offers hit detection based on up to 32 parameters per
 cell or bead, data mining, open architecture for data management and exchange,
 and control-setting capture for data validation.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X15688188
 
 SOURCE  Cytomation Inc.